Bryan Johnson, who runs the Blueprint longevity project, announced on July 21 that he has "cloned" himself — programming blood cells to an embryonic-like state in a petri dish he calls "baby-Bryan." He plans to test therapies on the cells, grow replacement organs, and inject young cells into himself. The announcement came two weeks after Johnson, 48, revealed his autoimmune gastritis diagnosis on July 6 — a chronic and incurable condition where the immune system attacks the stomach lining. Johnson didn't create a clone. He applied Yamanaka factors, reprogramming his blood cells into induced pluripotent stem cells (iPSCs) — an embryonic-like state where they can theoretically become any cell type. The Nobel-winning technology is real but a decade or more from producing transplantable organs; only 7 Parkinson's patients have received iPSC-derived treatment in clinical trials. Johnson hasn't published data, named a lab, or linked to a peer-reviewed paper.

1. The Science Works. Johnson's Claims Don't. (Nir Barzilai, Albert Einstein College of Medicine; Matt Kaeberlein, University of Washington)

The iPSC technology is Nobel-winning. What Johnson called a "clone" isn't.

iPSC cells are not a clone. What Johnson created — if he created it — is a culture of his own blood cells reprogrammed to an embryonic-like state. No second Bryan Johnson exists. No organ exists yet. Calling this a "clone" gets the science backwards: cloning produces a genetic duplicate organism; this produces a lab dish of his own cells at an earlier developmental state.

The technology is real, and it's early. iPSC research earned a Nobel Prize in 2012, and active clinical programs are working toward treating Parkinson's, vision loss, and heart disease. In practice, only 7 Parkinson's patients received iPSC-derived treatment in the first published clinical trial, a 2025 Nature study from Kyoto University. Growing functional, transplantable organs from iPSCs remains one of regenerative medicine's hardest unsolved problems.

Individual self-experiments don't produce science. Nir Barzilai, president of the Academy for Health & Lifespan Research at Albert Einstein College of Medicine, is direct: "Science is not on n = 1." Matt Kaeberlein at the University of Washington calls the longevity biohacking field a "signal-to-noise problem" — measuring everything, controlling nothing, makes it impossible to know what's working.

2. But Johnson Thinks He's Right to Push This Far. (Bryan Johnson, Blueprint)

The longevity community says critics consistently underestimate unconventional approaches.

Johnson's goals are real science — his timeline isn't. He wants to model his own biology, test experimental therapies on a cell culture version of himself, and eventually grow replacement organs. Each element of that roadmap exists in legitimate research programs at major universities. Johnson skipped the institutional scaffold and started now, alone.

Johnson says the diagnosis comes from his past — not his experiments. He blames the autoimmune gastritis on years of fast food, stress, and depression before Blueprint. To address it, he plans to experiment with engineered proteins that target the immune cells attacking his stomach lining. In Johnson's framing, this is another problem to solve, not evidence against his approach.

The pro-longevity community reads the criticism as predictable bias. Fight Aging! noted this week that self-experimentation in aging "is rarely presented in a good light" — the community reads that as institutional resistance to unconventional science, not as proof the paths are wrong.

3. His Own Disease Makes the Skeptics' Point. (Rupert Leong; David Gems, UCL Institute of Healthy Ageing)

A physician who reviewed his case raised what may be the sharpest counterargument.

The cure may have caused the diagnosis. Rupert Leong, a gastroenterologist, questioned Johnson's explanation, suggesting the autoimmune gastritis may instead result from "years of intensive and sometimes controversial self-experimentation." If that's right, the protocol designed to prevent disease triggered one — and Johnson's response is to accelerate.

Biohacking by wealthy individuals is "hubris," David Gems argues. The UCL Institute of Healthy Ageing researcher says Silicon Valley biohackers overestimate how cleanly tech problem-solving translates to biology, where decades of rigorous testing routinely fail to produce results that seemed obvious in early experiments.

Bypassing clinical trials distorts public understanding. Faye Mythen, founder of Reborne Longevity, describes high-profile biohackers as running "shadow phase two" experiments — self-funded, uncontrolled, and shared publicly in ways that mislead people about the readiness of therapies. The people who watch Johnson aren't researchers; they're patients looking for hope.

Where This Lands

Johnson's underlying vision — personalized cell therapy, iPSC-based organ replacement — is on real research roadmaps at major institutions. This is a story this month because of the pairing: a diagnosis that stripped him of one of his core claims to be succeeding, and a "clone" announcement two weeks later. Barzilai and Kaeberlein say self-experiments produce noise. Gems and Mythen say they produce something worse: a distorted public picture of what medicine can do today. Johnson says he'll keep going.

Sources